Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 474.0
(-0.84%)
JPY 474.0
(-0.84%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 84.56 Million JPY | -14.67% |
| 2022 | 99.1 Million JPY | -5.61% |
| 2021 | 104.99 Million JPY | 77.95% |
| 2020 | 59 Million JPY | 195.0% |
| 2019 | 20 Million JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 78 Million JPY | -7.76% |
| 2023 Q2 | 97.12 Million JPY | -0.36% |
| 2023 Q1 | 97.47 Million JPY | -1.64% |
| 2023 Q3 | 90.84 Million JPY | -6.47% |
| 2023 Q4 | 84.56 Million JPY | -6.92% |
| 2023 FY | 84.56 Million JPY | -14.67% |
| 2022 Q3 | 100 Million JPY | -2.3% |
| 2022 FY | 99.1 Million JPY | -5.61% |
| 2022 Q4 | 99.1 Million JPY | -0.9% |
| 2022 Q2 | 102.35 Million JPY | 0.0% |
| 2021 FY | 104.99 Million JPY | 77.95% |
| 2020 FY | 59 Million JPY | 195.0% |
| 2019 FY | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | 88.976% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 95.772% |
| Linical Co., Ltd. | 1.49 Billion JPY | 94.362% |
| Trans Genic Inc. | 1.32 Billion JPY | 93.628% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -10727.273% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 96.397% |
| AnGes, Inc. | 214.94 Million JPY | 60.66% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 20.859% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 99.866% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 92.374% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -197.729% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 90.342% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -116.545% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 95.399% |
| PeptiDream Inc. | 19.63 Billion JPY | 99.569% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | 47.51% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | 78.7% |
| Healios K.K. | 450 Million JPY | 81.209% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | -9.406% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | 89.065% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | 89.269% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | 82.79% |
| StemCell Institute Inc. | 6.67 Million JPY | -1166.642% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | 41.175% |